Core Insights - Carlsmed, Inc. reported a revenue of $12.1 million for Q2 2025, marking a 99% year-over-year growth from $6.1 million in Q2 2024 [1][3] - The company expects full-year revenue for 2025 to be between $45.5 million and $47.5 million, representing a growth of 67% to 75% compared to 2024 [4] Financial Performance - Gross profit for Q2 2025 was $8.9 million, up from $4.6 million in Q2 2024, with a gross margin of 73.4% compared to 75.0% in the prior year [3] - Operating expenses increased to $15.4 million in Q2 2025 from $10.9 million in Q2 2024, driven by higher sales and marketing expenses [3] - The net loss for Q2 2025 was $6.8 million, slightly higher than the $6.3 million loss in Q2 2024 [3] Operational Highlights - The company successfully completed its first personalized cervical spine surgery using the AI-enabled aprevo technology platform in July 2025 [2][3] - The aprevo cervical procedures received CMS New Technology Add-On Payment (NTAP) reimbursement effective October 1, 2025 [3] Market Positioning - Carlsmed's growth is attributed to the adoption of its AI-enabled aprevo technology platform, which is recognized for delivering better patient outcomes compared to traditional devices [2] - The company aims to establish itself as the new standard of care in spine fusion surgery as it enters the second half of 2025 [2]
UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results